
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corporation is expected to experience significant revenue growth driven by its MACI product, with projections indicating a high-teens annual growth rate due to both an increase in volumes and annual average selling price (ASP) improvements. The company has demonstrated a robust growth trajectory, anticipating approximately 21.2% year-over-year growth in MACI revenues for fiscal year 2026, supported by a strong conversion rate of biopsies to MACI. Additionally, the fourth quarter is projected to show a notable 26% quarter-over-quarter revenue increase, indicating a solid performance outlook for the company.
Bears say
Vericel Corp's financial outlook is negatively impacted by a downward revision of projected MACI revenues for FY26 and FY27, indicating a decrease of approximately 200 basis points. The company faces several risks affecting its revenue, including slower adoption of MACI and MACI Arthro by physicians, sluggish sales in the burn care segment, and potential disruptions related to the expansion of its sales force. Moreover, any failure to meet top-line expectations in a quarter could result in the stock trading at historical low valuation levels, further reflecting the company's challenging position in the market.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares